tiprankstipranks
Madrigal Pharmaceuticals Inc (GB:0JXI)
LSE:0JXI
UK Market
0JXI
Madrigal Pharmaceuticals
RESEARCH TOOLSreports

Madrigal Pharmaceuticals (0JXI) Share Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

0JXI Analyst Ratings

Strong Buy
13Ratings
Strong Buy
12 Buy
1 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Madrigal
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0JXI Stock 12 Month Forecast

Average Price Target

$689.08
▲(28.07% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Madrigal Pharmaceuticals in the last 3 months. The average price target is $689.08 with a high forecast of $962.00 and a low forecast of $543.00. The average price target represents a 28.07% change from the last price of $538.05.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"421":"$421","692":"$692","963":"$963","556.5":"$556.5","827.5":"$827.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":962,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$962.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":689.0769230769231,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$689.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":543,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$543.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[421,556.5,692,827.5,963],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,538.05,570.6615384615384,603.2730769230769,635.8846153846154,668.4961538461538,701.1076923076923,733.7192307692308,766.3307692307692,798.9423076923076,831.5538461538462,864.1653846153846,896.7769230769231,929.3884615384616,{"y":962,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,538.05,549.6674556213018,561.2849112426035,572.9023668639053,584.5198224852071,596.1372781065088,607.7547337278106,619.3721893491124,630.9896449704142,642.607100591716,654.2245562130178,665.8420118343195,677.4594674556213,{"y":689.0769230769231,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,538.05,538.4307692307692,538.8115384615385,539.1923076923076,539.5730769230769,539.9538461538461,540.3346153846154,540.7153846153846,541.0961538461538,541.4769230769231,541.8576923076923,542.2384615384615,542.6192307692307,{"y":543,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":434.523,"date":1756674000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":459.5,"date":1759266000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":422.18,"date":1761948000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":596,"date":1764540000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":588.62,"date":1767218400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":492.19,"date":1769896800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":435.52,"date":1772316000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":530.17,"date":1774990800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":516.71,"date":1777582800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":484.15,"date":1780261200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":525.42,"date":1782853200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":463.55,"date":1785531600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":538.05,"date":1788210000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$962.00Average Price Target$689.08Lowest Price Target$543.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on GB:0JXI
Edward Nash
Canaccord Genuity
Canaccord Genuity
$612
Buy
13.74%
Upside
Reiterated
08/11/26
Analysts Are Bullish on These Healthcare Stocks: Sagimet Biosciences, Inc. Class A (SGMT), BridgeBio Pharma (BBIO)
Wolfe Research Analyst forecast on GB:0JXI
Andy Chen
Wolfe Research
Wolfe Research
$605
Buy
12.44%
Upside
Upgraded
08/04/26
Madrigal upgraded to Outperform from Peer Perform at Wolfe ResearchMadrigal upgraded to Outperform from Peer Perform at Wolfe Research
Barclays Analyst forecast on GB:0JXI
Eliana Merle
Barclays
Barclays
$964→$962
Buy
78.79%
Upside
Reiterated
08/03/26
Barclays Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)
B. Riley Securities Analyst forecast on GB:0JXI
Unknown Analyst
B. Riley Securities
Not Ranked
B. Riley Securities
$670
Buy
24.52%
Upside
Initiated
07/31/26
Madrigal Pharmaceuticals (MDGL) Gets a Buy from B. Riley Securities
Truist Financial Analyst forecast on GB:0JXI
Srikripa Devarakonda
Truist Financial
Truist Financial
$709
Buy
31.77%
Upside
Reiterated
07/31/26
Madrigal Pharmaceuticals (MDGL) Gets a Buy from Truist Financial
H.C. Wainwright Analyst forecast on GB:0JXI
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$620
Buy
15.23%
Upside
Reiterated
07/31/26
Madrigal Therapeutics: Rezdiffra’s Expanding MASH Opportunity Supports Reiterated Buy Rating and Unchanged $620 Price Target
TD Cowen Analyst forecast on GB:0JXI
Ritu Baral
TD Cowen
TD Cowen
$644
Buy
19.69%
Upside
Reiterated
07/30/26
MDGL: Rezdiffra’s Strong Q2 Momentum, Robust Cash Position, and Expanding MASH Market Penetration Underpin TD Cowen Buy Rating
Bank of America Securities Analyst forecast on GB:0JXI
Jason Zemansky
Bank of America Securities
Bank of America Securities
$553→$543
Hold
0.92%
Upside
Reiterated
07/30/26
Neutral Stance Maintained as Madrigal’s Growth Prospects Tempered; Price Target Trimmed from $553 to $543
Wells Fargo Analyst forecast on GB:0JXI
Sadia Rahman
Wells Fargo
Wells Fargo
$685
Buy
27.31%
Upside
Initiated
07/27/26
Madrigal Pharmaceuticals initiated with an Overweight at Wells FargoMadrigal Pharmaceuticals initiated with an Overweight at Wells Fargo
UBS Analyst forecast on GB:0JXI
Ashwani Verma
UBS
UBS
$669
Buy
24.34%
Upside
Reiterated
07/21/26
Madrigal Pharmaceuticals (MDGL) Gets a Buy from UBS
Citizens JMP Analyst forecast on GB:0JXI
Jonathan Wolleben
Citizens JMP
Citizens JMP
$737→$739
Buy
37.35%
Upside
Reiterated
07/17/26
Madrigal Pharmaceuticals price target raised to $739 from $737 at CitizensMadrigal Pharmaceuticals price target raised to $739 from $737 at Citizens
Jefferies Analyst forecast on GB:0JXI
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$600
Buy
11.51%
Upside
Reiterated
06/30/26
Madrigal Pharmaceuticals (MDGL) Receives a Buy from Jefferies
Piper Sandler Analyst forecast on GB:0JXI
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$900
Buy
67.27%
Upside
Reiterated
06/29/26
Piper Sandler Remains a Buy on Madrigal Pharmaceuticals (MDGL)
Evercore ISI Analyst forecast on GB:0JXI
Michael DiFiore
Evercore ISI
Evercore ISI
$652→$649
Buy
20.62%
Upside
Reiterated
05/07/26
Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISIMadrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI
Clear Street Analyst forecast on GB:0JXI
Kaveri Pohlman
Clear Street
Clear Street
$533→$680
Buy
26.38%
Upside
Reiterated
05/06/26
Madrigal Pharmaceuticals price target raised to $680 from $533 at Clear StreetMadrigal Pharmaceuticals price target raised to $680 from $533 at Clear Street
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on GB:0JXI
Edward Nash
Canaccord Genuity
Canaccord Genuity
$612
Buy
13.74%
Upside
Reiterated
08/11/26
Analysts Are Bullish on These Healthcare Stocks: Sagimet Biosciences, Inc. Class A (SGMT), BridgeBio Pharma (BBIO)
Wolfe Research Analyst forecast on GB:0JXI
Andy Chen
Wolfe Research
Wolfe Research
$605
Buy
12.44%
Upside
Upgraded
08/04/26
Madrigal upgraded to Outperform from Peer Perform at Wolfe ResearchMadrigal upgraded to Outperform from Peer Perform at Wolfe Research
Barclays Analyst forecast on GB:0JXI
Eliana Merle
Barclays
Barclays
$964→$962
Buy
78.79%
Upside
Reiterated
08/03/26
Barclays Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)
B. Riley Securities Analyst forecast on GB:0JXI
Unknown Analyst
B. Riley Securities
Not Ranked
B. Riley Securities
$670
Buy
24.52%
Upside
Initiated
07/31/26
Madrigal Pharmaceuticals (MDGL) Gets a Buy from B. Riley Securities
Truist Financial Analyst forecast on GB:0JXI
Srikripa Devarakonda
Truist Financial
Truist Financial
$709
Buy
31.77%
Upside
Reiterated
07/31/26
Madrigal Pharmaceuticals (MDGL) Gets a Buy from Truist Financial
H.C. Wainwright Analyst forecast on GB:0JXI
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$620
Buy
15.23%
Upside
Reiterated
07/31/26
Madrigal Therapeutics: Rezdiffra’s Expanding MASH Opportunity Supports Reiterated Buy Rating and Unchanged $620 Price Target
TD Cowen Analyst forecast on GB:0JXI
Ritu Baral
TD Cowen
TD Cowen
$644
Buy
19.69%
Upside
Reiterated
07/30/26
MDGL: Rezdiffra’s Strong Q2 Momentum, Robust Cash Position, and Expanding MASH Market Penetration Underpin TD Cowen Buy Rating
Bank of America Securities Analyst forecast on GB:0JXI
Jason Zemansky
Bank of America Securities
Bank of America Securities
$553→$543
Hold
0.92%
Upside
Reiterated
07/30/26
Neutral Stance Maintained as Madrigal’s Growth Prospects Tempered; Price Target Trimmed from $553 to $543
Wells Fargo Analyst forecast on GB:0JXI
Sadia Rahman
Wells Fargo
Wells Fargo
$685
Buy
27.31%
Upside
Initiated
07/27/26
Madrigal Pharmaceuticals initiated with an Overweight at Wells FargoMadrigal Pharmaceuticals initiated with an Overweight at Wells Fargo
UBS Analyst forecast on GB:0JXI
Ashwani Verma
UBS
UBS
$669
Buy
24.34%
Upside
Reiterated
07/21/26
Madrigal Pharmaceuticals (MDGL) Gets a Buy from UBS
Citizens JMP Analyst forecast on GB:0JXI
Jonathan Wolleben
Citizens JMP
Citizens JMP
$737→$739
Buy
37.35%
Upside
Reiterated
07/17/26
Madrigal Pharmaceuticals price target raised to $739 from $737 at CitizensMadrigal Pharmaceuticals price target raised to $739 from $737 at Citizens
Jefferies Analyst forecast on GB:0JXI
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$600
Buy
11.51%
Upside
Reiterated
06/30/26
Madrigal Pharmaceuticals (MDGL) Receives a Buy from Jefferies
Piper Sandler Analyst forecast on GB:0JXI
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$900
Buy
67.27%
Upside
Reiterated
06/29/26
Piper Sandler Remains a Buy on Madrigal Pharmaceuticals (MDGL)
Evercore ISI Analyst forecast on GB:0JXI
Michael DiFiore
Evercore ISI
Evercore ISI
$652→$649
Buy
20.62%
Upside
Reiterated
05/07/26
Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISIMadrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI
Clear Street Analyst forecast on GB:0JXI
Kaveri Pohlman
Clear Street
Clear Street
$533→$680
Buy
26.38%
Upside
Reiterated
05/06/26
Madrigal Pharmaceuticals price target raised to $680 from $533 at Clear StreetMadrigal Pharmaceuticals price target raised to $680 from $533 at Clear Street
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ONCBeOne Medicines
DNLIDenali Therapeutics
SNDXSyndax Pharmaceuticals
ZYMEZymeworks
PTGXProtagonist Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Madrigal Pharmaceuticals

3 Months
Yasmeen RahimiPiper Sandler
Success Rate
11/15 ratings generated profit
73%
Average Return
+12.15%
Copying Yasmeen Rahimi's trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +12.15% per trade.
1 Year
Ritu BaralTD Cowen
Success Rate
25/27 ratings generated profit
93%
Average Return
+41.26%
Copying Ritu Baral's trades and holding each position for 1 Year would result in 92.59% of your transactions generating a profit, with an average return of +41.26% per trade.
2 Years
Ritu BaralTD Cowen
Success Rate
27/27 ratings generated profit
100%
Average Return
+72.62%
Copying Ritu Baral's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +72.62% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0JXI Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
2
4
5
5
3
Buy
11
11
19
12
11
Hold
2
3
5
4
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
18
29
21
17
In the current month, 0JXI has received 14 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 0JXI average Analyst price target in the past 3 months is 689.08.
Each month's total comprises the sum of three months' worth of ratings.

0JXI Financial Forecast

0JXI Earnings Forecast

Next quarter’s earnings estimate for 0JXI is -$0.86 with a range of -$2.00 to -$0.10. The previous quarter’s EPS was -$1.99. 0JXI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0JXI has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0JXI is -$0.86 with a range of -$2.00 to -$0.10. The previous quarter’s EPS was -$1.99. 0JXI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0JXI has Performed in-line its overall industry.

0JXI Sales Forecast

Next quarter’s sales forecast for 0JXI is $404.17M with a range of $384.70M to $424.74M. The previous quarter’s sales results were $364.25M. 0JXI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0JXI has Performed in-line its overall industry.
Next quarter’s sales forecast for 0JXI is $404.17M with a range of $384.70M to $424.74M. The previous quarter’s sales results were $364.25M. 0JXI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0JXI has Performed in-line its overall industry.

0JXI Stock Forecast FAQ

What is GB:0JXI’s average 12-month price target, according to analysts?
Based on analyst ratings, Madrigal Pharmaceuticals Inc’s 12-month average price target is 689.08.
    What is GB:0JXI’s upside potential, based on the analysts’ average price target?
    Madrigal Pharmaceuticals Inc has 28.07% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Madrigal Pharmaceuticals Inc a Buy, Sell or Hold?
          Madrigal Pharmaceuticals Inc has a consensus rating of Strong Buy, which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Madrigal Pharmaceuticals Inc’s share price target?
            The average share price target for Madrigal Pharmaceuticals Inc is 689.08. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $962.00 ,and the lowest forecast is $543.00. The average share price target represents 28.07% Increase from the current price of $538.05.
              What do analysts say about Madrigal Pharmaceuticals Inc?
              Madrigal Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of Madrigal Pharmaceuticals Inc?
                To buy shares of GB:0JXI, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.